Evidence map›Paper›PMID 37242504›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.

Luca Cegolon, Riccardo Pol, Omar Simonetti, Francesca Larese Filon, Roberto Luzzati

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 6 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 6 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Luca CegolonDepartment of Medical, Surgical & Health Sciences, University of Trieste, 34147 Trieste, Italy.ORCID 0000-0002-6285-7355
Riccardo PolInfectious Disease Unit, University Health Agency Giuliano-Isontina (ASUGI), 34129 Trieste, Italy.
Omar SimonettiInfectious Disease Unit, University Health Agency Giuliano-Isontina (ASUGI), 34129 Trieste, Italy.
Francesca Larese FilonDepartment of Medical, Surgical & Health Sciences, University of Trieste, 34147 Trieste, Italy.ORCID 0000-0002-7717-0417
Roberto LuzzatiDepartment of Medical, Surgical & Health Sciences, University of Trieste, 34147 Trieste, Italy.
University of Trieste · ITAzienda Sanitaria Universitaria Integrata di Trieste · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antiviralsCOVID-19high-risk patientshospitalizationMolnupiravirmonoclonal antibodiesmortalityNirmatrelvir/RitonavirPaxlovidSARS-CoV-2Sotrovimab

Identifiers

PMID37242504
PMCPMC10221734
OpenAlexW4378515324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.